

Rachel M Glicksman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2660755/publications.pdf>

Version: 2024-02-01

15
papers

146
citations

1937685

4
h-index

1199594

12
g-index

15
all docs

15
docs citations

15
times ranked

231
citing authors

#	ARTICLE	IF	CITATIONS
1	Enhancing International Cancer Organization Collaborations: King Hussein Cancer Center and Princess Margaret Cancer Centre Model for Collaboration. <i>Journal of Cancer Education</i> , 2022, 37, 763-769.	1.3	2
2	FACE Value of Patient-Reported Outcomes in Dose-Escalated Radiation Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 93-95.	0.8	0
3	Implementation of Cardiac Stereotactic Radiotherapy: From Literature to the Linac. <i>Cureus</i> , 2021, 13, e13606.	0.5	1
4	Mammographic Surveillance in Older Women With Breast Cancer in Canada and the United States: Are We Choosing Wisely?. <i>Practical Radiation Oncology</i> , 2021, 11, e384-e394.	2.1	1
5	Moving Unfavorable Small-Bowel Anatomy Away From the Prostate to Optimize Radiation Therapy Plans With the GU-Lok. <i>Practical Radiation Oncology</i> , 2021, 11, 510-514.	2.1	1
6	Reply to Wei Liu, Katherine Zukotynski, and Glenn Bauman's Letter to the Editor re: Rachel M. Glicksman, Ur Metser, Douglass Vines, et al. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. <i>Eur Urol</i> 2021;80:374-82. <i>European Urology</i> , 2021, 80, e79-e80.	1.9	1
7	Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. <i>European Urology</i> , 2021, 80, 374-382.	1.9	49
8	Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localized high risk prostate cancer: Long term results from a prospective clinical trial. <i>Radiotherapy and Oncology</i> , 2021, 163, 21-31.	0.6	7
9	Stereotactic Ablative Radiotherapy for the Management of Spinal Metastases. <i>JAMA Oncology</i> , 2020, 6, 567.	7.1	64
10	[¹⁸ F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial. <i>BMJ Open</i> , 2020, 10, e035959.	1.9	8
11	Use of combined androgen deprivation therapy with postoperative radiation treatment for prostate cancer: Impact of randomized trials on clinical practice. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 848.e1-848.e7.	1.6	3
12	The Capital Investment Strategy for Radiation therapy in Ontario: A Framework to Ensure Access to Radiation Therapy. <i>Advances in Radiation Oncology</i> , 2020, 5, 318-324.	1.2	5
13	Genomic Strategies to Personalize Use of Androgen Deprivation Therapy With Radiotherapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 13-20.	2.0	1
14	Stereotactic Radiotherapy for Pancreatic Cancer: A Single-Institution Experience. <i>Cureus</i> , 2020, 12, e10618.	0.5	1
15	Case series illustrating the synergistic use of hydrogel spacer and MR-guidance to increase the radiotherapeutic index for localized prostate cancer. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2019, 11, 22-25.	1.9	2